S. Melmed, A. Colao, A. Barkan, M. Molitch, A. Grossman et al., Guidelines for Acromegaly Management: An Update, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, 2009.
DOI : 10.1210/jc.2008-2421

C. Rajasoorya, I. Holdaway, P. Wrightson, D. Scott, and H. Ibbertson, Determinants of clinical outcome and survival in acromegaly, Clinical Endocrinology, vol.153, issue.4, 1994.
DOI : 10.2307/2281868

S. Orme, R. Mcnally, R. Cartwright, and P. Belchetz, Mortality and Cancer Incidence in Acromegaly, The Journal of Urology, vol.83, issue.8, pp.2730-2734, 1998.
DOI : 10.1097/00005392-199904000-00103

O. Dekkers, N. Biermasz, A. Pereira, J. Romijn, and J. Vandenbroucke, Mortality in Acromegaly: A Metaanalysis, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.1, pp.61-68, 2008.
DOI : 10.1210/jc.2007-1191

A. Dabrh, A. Mohammed, K. Asi, N. Farah, W. Wang et al., Surgical Interventions and Medical Treatments in Treatment-Na??ve Patients With Acromegaly: Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.11, 2014.
DOI : 10.1210/jc.2014-2900

P. Freda, S. Wardlaw, and K. Post, Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly, Journal of Neurosurgery, vol.89, issue.3, pp.353-361, 1998.
DOI : 10.3171/jns.1998.89.3.0353

. Acromegaly, An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab Oct, vol.3099, issue.11, pp.3933-51, 2014.

F. Castinetti, M. Nagai, I. Morange, H. Dufour, P. Caron et al., Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.9, pp.3400-3407, 2009.
DOI : 10.1210/jc.2008-2772

F. Castinetti, I. Morange, H. Dufour, J. Regis, and T. Brue, Radiotherapy and radiosurgery in acromegaly, Pituitary, vol.4, issue.Suppl 3, pp.3-10, 2009.
DOI : 10.1007/s11102-007-0078-y

G. Minniti, D. Traish, S. Ashley, A. Gonsalves, and M. Brada, Risk of Second Brain Tumor after Conservative Surgery and Radiotherapy for Pituitary Adenoma: Update after an Additional 10 Years, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.2, pp.800-804, 2005.
DOI : 10.1210/jc.2004-1152

P. Jenkins, P. Bates, M. Carson, P. Stewart, and J. A. Wass, Conventional Pituitary Irradiation Is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4, pp.1239-1284, 2006.
DOI : 10.1210/jc.2005-1616

L. Sandret, P. Maison, and P. Chanson, Place of Cabergoline in Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.5
DOI : 10.1210/jc.2010-2443

A. Giustina, P. Chanson, D. Kleinberg, M. Bronstein, D. Clemmons et al., Expert consensus document: A consensus on the medical treatment of acromegaly, Nature Reviews Endocrinology, vol.161, issue.4
DOI : 10.1038/nrendo.2014.21

P. Trainer, W. Drake, L. Katznelson, P. Freda, V. Herman-bonert et al., Treatment of Acromegaly with the Growth Hormone???Receptor Antagonist Pegvisomant, New England Journal of Medicine, vol.342, issue.16, pp.1171-1178, 2000.
DOI : 10.1056/NEJM200004203421604

A. Van-der-lely, R. Hutson, P. Trainer, G. Besser, A. Barkan et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, The Lancet, vol.358, issue.9295, pp.1754-1763, 2001.
DOI : 10.1016/S0140-6736(01)06844-1

A. Van-der-lely, B. Biller, T. Brue, M. Buchfelder, E. Ghigo et al., Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.5, pp.1589-97, 2012.
DOI : 10.1210/jc.2011-2508

URL : https://hal.archives-ouvertes.fr/hal-00701564

I. Schreiber, M. Buchfelder, M. Droste, K. Forssmann, K. Mann et al., Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study, European Journal of Endocrinology, vol.156, issue.1, pp.75-82, 2007.
DOI : 10.1530/eje.1.02312

S. Melmed, A. Colao, A. Barkan, M. Molitch, A. Grossman et al., Guidelines for Acromegaly Management: An Update, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, 2009.
DOI : 10.1210/jc.2008-2421

J. Feenstra, W. De-herder, S. Ten-have, A. Van-den-beld, R. Feelders et al., Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly, The Lancet, vol.365, issue.9471, pp.1644-1650, 2005.
DOI : 10.1016/S0140-6736(05)63011-5

P. Trainer, ACROSTUDY: the first 5 years, European Journal of Endocrinology, vol.161, issue.Suppl 1, pp.19-24, 2009.
DOI : 10.1530/EJE-09-0322

J. Jørgensen, U. Feldt-rasmussen, J. Frystyk, J. Chen, L. Kristensen et al., Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.10, pp.5627-5658, 2005.
DOI : 10.1210/jc.2005-0531

S. Neggers, M. Van-aken, J. Janssen, R. Feelders, W. De-herder et al., Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, 2007.
DOI : 10.1210/jc.2007-1234

S. Neggers, M. Van-aken, W. De-herder, R. Feelders, J. A. Janssen et al., Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.10, 2008.
DOI : 10.1210/jc.2008-0669

S. Neggers, W. De-herder, J. A. Janssen, . Mjl, R. Feelders et al., Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients, European Journal of Endocrinology, vol.160, issue.4, pp.529-562, 2009.
DOI : 10.1530/EJE-08-0843

P. Trainer, S. Ezzat, D. Souza, G. Layton, G. Strasburger et al., A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clinical Endocrinology, vol.87, issue.4, pp.549-57, 2009.
DOI : 10.1111/j.1365-2265.2009.03620.x

S. Neggers, W. De-herder, R. Feelders, and A. Van-der-lely, Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary, pp.253-261, 2011.

A. Van-der-lely, I. Bernabeu, J. Cap, P. Caron, A. Colao et al., Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone, European Journal of Endocrinology, vol.164, issue.3, pp.325-358, 2011.
DOI : 10.1530/EJE-10-0867

A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli et al., Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes, Journal of Experimental & Clinical Cancer Research, vol.32, issue.1, p.40, 2013.
DOI : 10.1210/jc.2010-1742

S. Neggers, S. Franck, F. De-rooij, A. Dallenga, R. Poublon et al., Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.10, 2014.
DOI : 10.1210/jc.2014-2032

M. Bex, R. Abs, T. Sjoen, G. Mockel, J. Velkeniers et al., AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects, European Journal of Endocrinology, vol.157, issue.4, pp.399-409, 2007.
DOI : 10.1530/EJE-07-0358

J. Ayuk, R. Clayton, G. Holder, M. Sheppard, P. Stewart et al., Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.4, pp.1613-1620, 2004.
DOI : 10.1210/jc.2003-031584

I. Holdaway, M. Bolland, and G. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, European Journal of Endocrinology, vol.159, issue.2, pp.89-95, 2008.
DOI : 10.1530/EJE-08-0267

A. Mestron, S. Webb, R. Astorga, P. Benito, M. Catala et al., Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), European Journal of Endocrinology, vol.151, issue.4, pp.439-485, 2004.
DOI : 10.1530/eje.0.1510439

M. Sherlock, R. Reulen, A. Aragon-alonso, J. Ayuk, R. Clayton et al., A Paradigm Shift in the Monitoring of Patients With Acromegaly: Last Available Growth Hormone May Overestimate Risk, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.478-85, 2014.
DOI : 10.1210/jc.2013-2450

I. Holdaway, Treatment of Acromegaly, Hormone Research in Paediatrics, vol.62, issue.3, pp.79-92, 2004.
DOI : 10.1159/000080505

I. Holdaway, R. Rajasoorya, and G. Gamble, Factors Influencing Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.2, pp.667-74, 2004.
DOI : 10.1210/jc.2003-031199

R. Kauppinen-mäkelin, T. Sane, A. Reunanen, M. Välimäki, L. Niskanen et al., A Nationwide Survey of Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.7, pp.4081-4087, 2005.
DOI : 10.1210/jc.2004-1381

A. Colao, D. Ferone, P. Marzullo, and G. Lombardi, Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management, Endocrine Reviews, vol.25, issue.1, pp.102-52, 2004.
DOI : 10.1210/er.2002-0022

A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary, pp.50-58, 2012.

A. Colao, R. Baldelli, P. Marzullo, E. Ferretti, D. Ferone et al., Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.1, pp.193-202, 2000.
DOI : 10.1210/jc.85.1.193

F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli et al., Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.11, pp.4271-4278, 2007.
DOI : 10.1210/jc.2007-1213

C. Berg, S. Petersenn, H. Lahner, B. Herrmann, M. Buchfelder et al., Cardiovascular Risk Factors in Patients with Uncontrolled and Long-Term Acromegaly: Comparison with Matched Data from the General Population and the Effect of Disease Control, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.8, pp.3648-56, 2010.
DOI : 10.1210/jc.2009-2570

B. Herrmann, C. Bruch, B. Saller, T. Bartel, S. Ferdin et al., Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy, Clinical Endocrinology, vol.260, issue.5, 2002.
DOI : 10.1016/0735-1097(95)00505-6

E. Kuhn, L. Maione, A. Bouchachi, M. Rozière, S. Salenave et al., Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study, European Journal of Endocrinology, vol.173, issue.5, p.2015
DOI : 10.1530/EJE-15-0500

T. Rosén and B. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism, The Lancet, vol.336, issue.8710, pp.285-293, 1990.
DOI : 10.1016/0140-6736(90)91812-O

M. Sherlock, A. Alonso, A. Reulen, R. Ayuk, J. Clayton et al., Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly, Clinical Endocrinology, vol.11, issue.1, pp.74-81, 2009.
DOI : 10.1111/j.1365-2265.2008.03461.x

N. Møller, J. Jørgensen, N. Abildgård, L. Orskov, O. Schmitz et al., Effects of growth hormone on glucose metabolism, Horm Res, vol.36, issue.1, pp.32-37, 1991.

H. Biering, G. Knappe, H. Gerl, and H. Lochs, Diabetes-Haufigkeit bei Akromegalie und Cushing-Syndrom, Acta Medica Austriaca, vol.27, issue.1, pp.27-31, 2000.
DOI : 10.1046/j.1563-2571.2000.00106.x

A. Dreval, I. Trigolosova, I. Misnikova, Y. Kovalyova, R. Tishenina et al., Prevalence of diabetes mellitus in patients with acromegaly, Endocrine Connections, vol.3, issue.2, pp.93-101, 2014.
DOI : 10.1530/EC-14-0021

G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson et al., Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1500-1508, 2009.
DOI : 10.1210/jc.2008-2332

A. Colao, R. Auriemma, S. Savastano, M. Galdiero, L. Grasso et al., Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2907-2921, 2009.
DOI : 10.1210/jc.2008-2627

W. Drake, C. Parkinson, S. Akker, J. Monson, G. Besser et al., Successful treatment of resistant acromegaly with a growth hormone receptor antagonist, European Journal of Endocrinology, vol.145, issue.4, pp.451-457, 2001.
DOI : 10.1530/eje.0.1450451

A. Mestron, S. Webb, R. Astorga, P. Benito, M. Catala et al., Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), European Journal of Endocrinology, vol.151, issue.4, pp.439-485, 2004.
DOI : 10.1530/eje.0.1510439

E. Kuhn, L. Maione, A. Bouchachi, M. Rozière, S. Salenave et al., Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study, European Journal of Endocrinology, vol.173, issue.5, p.2015
DOI : 10.1530/EJE-15-0500

J. Roemmler, B. Gutt, R. Fischer, S. Vay, A. Wiesmeth et al., Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath Schlaf Atm, pp.1247-53, 2012.

A. Barkan, Acromegalic arthropathy. Pituitary, pp.263-267, 2001.

G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra et al., Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.100, issue.2, pp.384-94, 2015.
DOI : 10.1210/jc.2014-2937

W. Fairfield, G. Sesmilo, L. Katznelson, K. Pulaski, P. Freda et al., Effects of a growth hormone receptor antagonist on bone markers in acromegaly, Clinical Endocrinology, vol.84, issue.3, pp.385-90, 2002.
DOI : 10.1056/NEJM200004203421604

M. Terzolo, G. Reimondo, M. Gasperi, R. Cozzi, R. Pivonello et al., Colonoscopic Screening and Follow-Up in Patients with Acromegaly: A Multicenter Study in Italy, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.1, pp.84-90, 2005.
DOI : 10.1210/jc.2004-0240

L. Hofland and S. Lamberts, The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance, Endocrine Reviews, vol.24, issue.1, pp.28-47, 2003.
DOI : 10.1210/er.2000-0001

G. Taboada, R. Luque, W. Bastos, R. Guimarães, J. Marcondes et al., Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, European Journal of Endocrinology, vol.156, issue.1, pp.65-74, 2007.
DOI : 10.1530/eje.1.02313

A. Ben-shlomo and S. Melmed, Somatostatin agonists for treatment of acromegaly, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.192-200, 2008.
DOI : 10.1016/j.mce.2007.11.024

A. Colao, M. Bronstein, P. Freda, F. Gu, C. Shen et al., Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.3, pp.791-800, 2014.
DOI : 10.1210/jc.2013-2480

M. Gadelha, M. Bronstein, T. Brue, M. Coculescu, M. Fleseriu et al., Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial, The Lancet Diabetes & Endocrinology, vol.2, issue.11, pp.875-84, 2014.
DOI : 10.1016/S2213-8587(14)70169-X

S. Melmed, Medical progress: Acromegaly, N Engl J Med Dec, vol.14355, issue.24, pp.2558-73, 2006.

S. Melmed, D. Kleinberg, V. Bonert, and M. Fleseriu, Acromegaly: Assessing the Disorder and Navigating Therapeutic Options for Treatment, Endocrine Practice, vol.20, issue.Supplement 1, pp.7-17, 2014.
DOI : 10.4158/EP14430.RA

S. Alvarellos, Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis, PloS One, vol.8, issue.4, p.61523, 2013.

M. Shen, X. Shou, Y. Wang, Z. Zhang, J. Wu et al., Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study, Endocrine Journal, vol.57, issue.12, pp.1035-1079, 2010.
DOI : 10.1507/endocrj.K10E-203

S. Carlsen, M. Lund-johansen, T. Schreiner, S. Aanderud, Ø. Johannesen et al., Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2984-90, 2008.
DOI : 10.1210/jc.2008-0315

Z. Mao, Y. Zhu, H. Tang, D. Wang, J. Zhou et al., Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial, European Journal of Endocrinology, vol.162, issue.4, pp.661-667, 2010.
DOI : 10.1530/EJE-09-0908

N. Karavitaki, H. Turner, C. Adams, S. Cudlip, J. Byrne et al., Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide, Clinical Endocrinology, vol.87, issue.6, pp.970-975, 2008.
DOI : 10.1111/j.1365-2265.2006.02467.x

A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L. Cavallo et al., Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.1, 2006.
DOI : 10.1210/jc.2005-1208

R. Jallad, N. Musolino, S. Kodaira, V. Cescato, and M. Bronstein, Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?, Clinical Endocrinology, vol.67, issue.2
DOI : 10.1210/jc.83.10.3411

P. Petrossians, L. Borges-martins, C. Espinoza, A. Daly, D. Betea et al., Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs, European Journal of Endocrinology, vol.152, issue.1, 2005.
DOI : 10.1530/eje.1.01824

C. Newman, S. Melmed, P. Snyder, W. Young, L. Boyajy et al., Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study., The Journal of Clinical Endocrinology & Metabolism, vol.80, issue.9, 1995.
DOI : 10.1210/jcem.80.9.7673422

J. Bevan, The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, pp.1856-63, 2005.
DOI : 10.1210/jc.2004-1093

T. Howlett, D. Willis, G. Walker, J. Wass, P. Trainer et al., UKAR-3) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists, Clin Endocrinol, vol.79, issue.5, pp.689-99, 2013.

A. Heck, G. Ringstad, S. Fougner, O. Casar-borota, T. Nome et al., Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly, Clinical Endocrinology, vol.83, issue.1, pp.72-80
DOI : 10.1111/j.1365-2265.2011.04286.x

A. Heck, K. Emblem, O. Casar-borota, J. Bollerslev, and G. Ringstad, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly, Endocrine, vol.95, issue.7, pp.333-376, 2016.
DOI : 10.1007/s12020-015-0766-8

R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio et al., Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4
DOI : 10.1210/jc.2005-2347

A. Colao, R. Pivonello, R. Auriemma, M. Galdiero, S. Savastano et al., Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly, European Journal of Endocrinology, vol.157, issue.5, pp.579-87, 2007.
DOI : 10.1530/EJE-07-0383

A. Colao, M. Bronstein, P. Freda, F. Gu, C. Shen et al., Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.3, pp.791-800, 2014.
DOI : 10.1210/jc.2013-2480

M. Mercado, F. Borges, H. Bouterfa, T. Chang, A. Chervin et al., (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-68, 2007.
DOI : 10.1210/jc.85.2.781

S. Melmed, D. Cook, J. Schopohl, M. Goth, K. Lam et al., Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel?? therapy: a randomized, placebo-controlled, multicenter study with a 52??week open extension, Pituitary, vol.94, issue.1, pp.18-28, 2010.
DOI : 10.1007/s11102-009-0191-1

P. Freda, L. Katznelson, A. Van-der-lely, C. Reyes, S. Zhao et al., Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.8, pp.4465-73, 2005.
DOI : 10.1210/jc.2005-0260

M. Mercado, F. Borges, H. Bouterfa, T. Chang, A. Chervin et al., (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-68, 2007.
DOI : 10.1210/jc.85.2.781

L. Octreotide, surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study, Clin Endocrinol, vol.70, issue.5, pp.757-68, 2009.

P. Caron, J. Bevan, S. Petersenn, D. Flanagan, A. Tabarin et al., Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.4, 2014.
DOI : 10.1210/jc.2013-3318

A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani et al., Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly, PLoS ONE, vol.94, issue.8 Suppl 1, p.36411, 2012.
DOI : 10.1371/journal.pone.0036411.s002

A. Colao, R. Auriemma, A. Rebora, M. Galdiero, E. Resmini et al., Significant tumour shrinkage after 12??months of lanreotide Autogel-120??mg treatment given first-line in acromegaly, Clinical Endocrinology, vol.68, issue.2, pp.237-282, 2009.
DOI : 10.1111/j.1365-2265.2008.03503.x

A. Colao, R. Auriemma, M. Galdiero, G. Lombardi, and R. Pivonello, Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3746-56, 2009.
DOI : 10.1210/jc.2009-0941

A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi et al., High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial, European Journal of Endocrinology, vol.161, issue.2, pp.331-339, 2009.
DOI : 10.1530/EJE-09-0372

R. Attanasio, A. Mainolfi, F. Grimaldi, R. Cozzi, M. Montini et al., Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients, Journal of Endocrinological Investigation, vol.338, issue.2, pp.704-714, 2008.
DOI : 10.1007/BF03346419

A. Colao, R. Auriemma, S. Savastano, M. Galdiero, L. Grasso et al., Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2907-2921, 2009.
DOI : 10.1210/jc.2008-2627

R. Henry, T. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-saylan et al., Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3446-53, 2013.
DOI : 10.1210/jc.2013-1771

D. Clemmons, K. Chihara, P. Freda, K. Ho, A. Klibanski et al., Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.10, pp.4759-67, 2003.
DOI : 10.1210/jc.2003-030518

A. Muller, J. Kopchick, A. Flyvbjerg, and A. Van-der-lely, Growth Hormone Receptor Antagonists, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.4, pp.1503-1514, 2004.
DOI : 10.1210/jc.2002-022049

P. Trainer, Lessons from 6 years of GH receptor antagonist therapy for acromegaly, J Endocrinol Invest, vol.26, pp.44-52, 2003.

J. Veldhuis, M. Bidlingmaier, S. Anderson, Z. Wu, and C. Strasburger, Lowering Total Plasma Insulin-Like Growth Factor I Concentrations by Way of a Novel, Potent, and Selective Growth Hormone (GH) Receptor Antagonist, Pegvisomant (B2036-Peg), Augments the Amplitude of GH Secretory Bursts and Elevates Basal/Nonpulsatile GH Release in Healthy Women and Men, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.3304-3314, 2001.
DOI : 10.1210/jc.86.7.3304

J. Kopchick, C. Parkinson, E. Stevens, and P. Trainer, Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly, Endocrine Reviews, vol.23, issue.5, pp.623-669, 2002.
DOI : 10.1210/er.2001-0022

C. Higham, T. Chung, J. Lawrance, W. Drake, and P. Trainer, Long-term experience of pegvisomant therapy as a treatment for acromegaly, Clinical Endocrinology, vol.90, issue.1, pp.86-91, 2009.
DOI : 10.1111/j.1365-2265.2008.03469.x

A. Ramos-leví, I. Bernabeu, C. Álvarez-escolá, J. Aller, T. Lucas et al., Long-term treatment with pegvisomant for acromegaly: a 10-year experience, Clinical Endocrinology, vol.154, issue.Suppl 3, pp.540-50
DOI : 10.1111/cen.12993

A. Colao, R. Pivonello, R. Auriemma, D. Martino, M. Bidlingmaier et al., Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance, European Journal of Endocrinology, vol.154, issue.3, pp.467-77, 2006.
DOI : 10.1530/eje.1.02112

M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller et al., Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study, European Journal of Endocrinology, vol.161, issue.1, pp.27-35, 2009.
DOI : 10.1530/EJE-08-0910

J. Buhk, S. Jung, M. Psychogios, S. Göricke, S. Hartz et al., Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.2, 2010.
DOI : 10.1210/jc.2009-1239

M. Marazuela, A. Paniagua, M. Gahete, T. Lucas, C. Alvarez-escolá et al., Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.2, pp.251-260, 2011.
DOI : 10.1210/jc.2010-1742

L. Frohman and V. Bonert, Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy, Pituitary, vol.342, issue.3, pp.283-292, 2007.
DOI : 10.1007/s11102-007-0042-x

I. Hodish and A. Barkan, Long-term effects of pegvisomant in patients with acromegaly, Nature Clinical Practice Endocrinology & Metabolism, vol.90, issue.6, pp.324-356, 2008.
DOI : 10.1038/ncpendmet0831

J. Kopchick, E. List, B. Kelder, E. Gosney, and D. Berryman, Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications, Molecular and Cellular Endocrinology, vol.386, issue.1-2, pp.34-45, 2014.
DOI : 10.1016/j.mce.2013.09.004

A. Giustina, M. Ambrosio, B. Peccoz, P. Bogazzi, F. Cannavo-'s et al., Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline, Journal of Endocrinological Investigation, vol.92, issue.6, pp.1017-1047, 2014.
DOI : 10.1007/s40618-014-0146-x

I. Bernabeu, M. Marazuela, T. Lucas, L. Loidi, C. Alvarez-escolá et al., Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome, J Clin Endocrinol Metab, 2010.

H. Biering, B. Saller, J. Bauditz, M. Pirlich, B. Rudolph et al., Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis, European Journal of Endocrinology, vol.154, issue.2, 2006.
DOI : 10.1530/eje.1.02079

S. Neggers and A. Van-der-lely, Combination treatment with somatostatin analogues and pegvisomant in acromegaly, Growth Hormone & IGF Research, vol.21, issue.3, pp.129-162, 2011.
DOI : 10.1016/j.ghir.2011.03.004

P. Trainer, S. Ezzat, D. Souza, G. Layton, G. Strasburger et al., A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clinical Endocrinology, vol.87, issue.4, pp.549-57, 2009.
DOI : 10.1111/j.1365-2265.2009.03620.x

M. Madsen, S. Fisker, U. Feldt-rasmussen, M. Andreassen, L. Kristensen et al., Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly, Clinical Endocrinology, vol.51, issue.Suppl 1
DOI : 10.1111/cen.12239

G. Sesmilo, E. Resmini, I. Bernabeu, J. Aller, A. Soto et al., Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study, Clinical Endocrinology, vol.113, issue.6, pp.883-90, 2014.
DOI : 10.1111/cen.12440

W. Drake, S. Rowles, M. Roberts, F. Fode, G. Besser et al., Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant, European Journal of Endocrinology, vol.149, issue.6, pp.521-528, 2003.
DOI : 10.1530/eje.0.1490521

D. Marinis, L. Bianchi, A. Fusco, A. Cimino, V. Mormando et al., Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA, Pituitary, vol.52, issue.3, pp.227-259, 2007.
DOI : 10.1007/s11102-007-0037-7

A. Bianchi, G. Mazziotti, L. Tilaro, V. Cimino, F. Veltri et al., Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly, Pituitary, vol.145, issue.9, pp.196-205, 2009.
DOI : 10.1007/s11102-008-0157-8

T. Ankrah-tetteh, S. Wijeratne, and R. Swaminathan, Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1, Annals of Clinical Biochemistry, vol.45, issue.2, pp.167-176, 2008.
DOI : 10.1258/acb.2007.007103

A. Colao, R. Auriemma, G. Lombardi, and R. Pivonello, Resistance to Somatostatin Analogs in Acromegaly, Endocrine Reviews, vol.32, issue.2, pp.247-71
DOI : 10.1210/er.2010-0002

P. Caron, M. Bex, D. Cullen, U. Feldt-rasmussen, P. Alfonso et al., One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelR, Clinical Endocrinology, vol.143, issue.6, pp.734-774, 2004.
DOI : 10.1001/archinte.151.8.1573

E. Machado, G. Taboada, L. Neto, F. Haute, . Van et al., Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR??, Growth Hormone & IGF Research, vol.18, issue.5, pp.389-93, 2008.
DOI : 10.1016/j.ghir.2008.02.001

R. Cohen, P. Chanson, E. Bruckert, J. Timsit, A. Legrand et al., Effects of octreotide on lipid metabolism in acromegaly. Horm Metab Res Horm Stoffwechselforschung Horm Métabolisme, pp.397-400, 1992.

M. Droste, J. Domberg, M. Buchfelder, K. Mann, A. Schwanke et al., Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels, European Journal of Endocrinology, vol.171, issue.1, pp.59-68
DOI : 10.1530/EJE-13-0438

C. Parkinson, P. Burman, M. Messig, and P. Trainer, Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.1, pp.190-195, 2007.
DOI : 10.1210/jc.2006-1412

J. Kratzsch, K. Keliner, T. Zilkens, H. Schmidt-gayk, T. Selisko et al., Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus, Clinical Endocrinology, vol.44, issue.6, pp.673-681, 1996.
DOI : 10.1046/j.1365-2265.1996.672494.x

S. Neggers, W. De-herder, R. Feelders, and A. Van-der-lely, Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary, pp.253-261, 2011.

D. Rose and D. Clemmons, Growth hormone receptor antagonist improves insulin resistance in acromegaly, Growth Hormone & IGF Research, vol.12, issue.6, pp.418-442, 2002.
DOI : 10.1016/S1096-6374(02)00083-7

C. Parkinson, W. Drake, G. Wieringa, A. Yates, G. Besser et al., Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly, Clinical Endocrinology, vol.56, issue.3, pp.303-314, 2002.
DOI : 10.1001/archinte.151.8.1573

B. Angelin and M. Rudling, Growth hormone and hepatic lipoprotein metabolism, Current Opinion in Lipidology, vol.5, issue.3, pp.160-165, 1994.
DOI : 10.1097/00041433-199405030-00002

M. Material, Retrospective study single center about 29 acromegaly patients operated or not, not controlled after treatment with SSA first or second generation (IGF- 1> 1 ULN)

. Ldlc, 02) were significantly improved after introduction of PEGV. There was no increase in the size of the adenoma. Moderate liver enzyme elevations (> 3 ULN)